Apoptotic Platelet Events Are Not Observed in Severe von Willebrand Disease-Type 2B Mutation p.V1316M

Eliane Berrou1, Alexandre Kauskot1, Frédéric Adam1, Amélie Harel1, Paulette Legendre1, Cécile Lavenu Bombled1,2, Chantal Rothschild3, Nicolas Prevost4, Olivier D. Christophe1, Peter J. Lenting1, Cécile V. Denis1, Jean-Philippe Rosa1, Marijke Bryckaert1 *

1 INSERM UMR_S 1176, Univ. Paris-Sud, Université Paris-Saclay, 94276, Le Kremlin-Bicêtre, France,
2 Service Hématologie Biologique, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France,
3 Centre Hémophilie, Hôpital Necker, Paris, France, 4 Kyoto Gakuen University, Kameoka, Japan

* marijke.bryckaert@inserm.fr

Abstract

Thrombocytopenia and increased platelet clearance observed in von Willebrand disease-type 2B (VWD-2B) may be explained by platelet apoptosis triggered by the constitutive binding of VWF to its receptor, glycoprotein Ib (GPIb). Apoptosis was assessed in platelets from two patients with a severe VWD-2B mutation VWF/p.V1316M and from mice transiently expressing VWF/p.V1316M. We now report that the VWD-2B mutation VWF/p.V1316M which binds spontaneously to its receptor GPIbα does not induce apoptosis. In 2 unrelated patients (P1 and P2) exhibiting different VWF plasma levels (70% and 36%, respectively, compared with normal pooled human plasma given as 100%), inner transmembrane depolarization of mitochondria, characteristic of apoptotic events was undetectable in platelets, whether washed or in whole blood. No or a moderate phosphatidyl serine (PS) exposure as measured by annexin-V staining was observed for P1 and P2, respectively. Expression of pro-apoptotic proteins Bak and Bax, and caspase-3 activity were similar to control platelets. In the VWD-2B mouse model expressing high levels of mVWF/p.V1316M (423%), similar to what is found in inflammatory pathologies, no significant difference was observed between mice expressing mVWF/WT and mVWF/p.V1316M. These results strongly argue against apoptosis as a mechanism for the thrombocytopenia of severe VWD-2B exhibiting the VWF/p.V1316M mutation.

Introduction

von Willebrand factor (VWF) is a multimeric glycoprotein essential for primary hemostasis.[1] Indeed, platelet adhesion is initiated by the interaction of VWF with the platelet glycoprotein Ib-IX-V (GPIb-IX-V) receptor complex whereas stable adhesion requires the interaction of VWF with the integrin αIIbβ3.[2] The physiological role of VWF is illustrated in patients with the von Willebrand disease (VWD), which is characterized by a bleeding tendency. Among VWD, VWD-2B is characterized by gain-of-function mutations in the VWF-A1 domain,
which promote constitutive binding of mutant VWF to GPIbα.[3, 4] The bleeding tendency observed in these patients is often explained by the absence of high molecular weight VWF multimers, as well as to the unavailability of GPIbα due to constitutively bound 2B mutants and finally to thrombocytopenia. The variability of the degree of thrombocytopenia is mutation-dependent but the bleeding tendency is directly correlated with platelet counts.[4] Thrombocytopenia in VWD-2B may be explained by different mechanisms. First, thrombocytopenia may originate from impaired platelet production since VWD VWF appears to alter megakaryopoiesis.[5] In a second mechanism, thrombocytopenia may originate from the incorporation of platelets into circulating VWF/platelet aggregates [6] and increased clearance of platelets.

A third putative mechanism is platelet apoptosis. GPIbα-VWF interactions have been proposed to induce apoptotic events in platelets, based on the fact that in the presence of ristocetin, VWF induces depolarization of the mitochondrial inner transmembrane potential, phosphatidyl serine exposure and elevation of proapoptotic proteins Bak and Bax and caspase-3 activity.[8] In these conditions, the association of 14-3-3ζ with the cytoplasmic domain of GPIbα is essential for apoptotic signaling. Another study also suggested that platelet apoptosis can occur through GPIbα clustering.[9]

To investigate whether apoptosis participates in thrombocytopenia in VWD-2B patients, we searched for apoptotic markers in platelets isolated from two patients with a severe VWF-type 2B mutation (VWF/p.V1316M). We also examined apoptotic events in platelets isolated from a mouse model expressing the same mutation [10] associated with increased clearance in platelets. [7] We now report that apoptosis is not involved in thrombocytopenia observed in patients with VWD-2B or in mice expressing high levels of mVWF/p.V1316M. Depolarization of the mitochondrial inner transmembrane potential, phosphatidyl serine exposure and caspase-3 activity were not observed and expression of proapoptotic proteins Bak and Bax is normal.

Material and Methods

Material
Tetramethylrhodamine ethyl ester (TMRE) was purchased from Molecular Probes. ABT-737 was from Merck Millipore. PE Annexin V, mouse antibodies directed against Bcl-xL, gelsolin were obtained from Becton Dickinson. Monoclonal antibody directed against caspase-3 and polyclonal antibody directed against Bak were obtained from Cell Signaling Technology. Monoclonal antibody directed against Bax was from Epitomics. Polyclonal antibody directed against calpain 1 was obtained from Abcam.

Patients
Two patients carrying a VWF mutation associated with VWD-type 2B were enrolled in this study after informed written consent in accordance with the Declaration of Helsinki. The study was approved by the Ethic Committee of the Institut National de la Santé et de la Recherche Médicale Recherche Biomédicale (INSERM RBM) 01–14. The patients (P1 and P2) are two men carriers of the pVal1316Met (V1316M) substitution. The bleeding score was high for the two patients associated with a loss of high-molecular-weight VWF multimers and a low platelet count (P1: 80x10⁹ platelets/L; P2: 40x10⁹ platelets/L) at the time of examination (Table 1). Small aggregates were detected in patients (S1 Fig).

Preparation of human washed platelets
Venous blood was collected in 10% (vol/vol) ACD-A (75 mM trisodium citrate, 44 mM citric acid, 136 mM glucose, pH4) for the experiments of washed platelets. The blood sample was
centrifuged at low speed (50 g) to recover enlarged platelets in platelet rich plasma (PRP) as previously described.[11] After centrifugation, isolated platelets were washed twice in the presence of apyrase (100 mU/mL) and prostaglandin E1 (1 μM). Then platelets were resuspended in Tyrode buffer (137 mM NaCl, 2 mM KCl, 0.3 mM NaH$_2$PO$_4$, 1 mM MgCl$_2$, 5.5 mM glucose, 5 mM N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid, 12 mM NaHCO$_3$, 2 mM CaCl$_2$, pH 7.3).

### Mouse strains

VWF-deficient mice were backcrossed onto a C57BL/6 background for more than twelve generations, yielding congenic C57BL/6 VWF$^{-/-}$ mice. All the experimental procedures were carried out in accordance with the European legislation concerning the use of laboratory animals and approved by the Animal Care and Ethical Committee of University Paris-Sud CEEA 26 under the number 2012-039.

### Hydrodynamic injection

Mice were injected with pLIVE or pLIVE-mVWF encoding mVWF/WT or pLIVE-mV1316M plasmids (30 μg) using the hydrodynamic injection method, as previously described.[10] After three days, blood was collected. Compared with normal pooled mouse plasma (100%), average antigen VWF levels were 297.3% ± 59.6% and 423.3% ± 61.1% for WT mVWF and mVWF/p.V1316M respectively. Expression of mutant mVWF/p.V1316M correlated with a severe macrothrombocytopenia (301 ± 93x10$^9$ platelets/L) as previously described.[10]

### Blood collection and preparation of murine washed platelets

Mice were anesthetized by intraperitoneal injection of sodium pentobarbital (60 mg/kg) and blood was collected by cardiac puncture and mixed with 80 μM PPACK and 10% (vol/vol) ACD-C buffer (124 mM sodium citrate, 130 mM citric acid, 110 mM dextrose, pH 6.5). Isolated platelets were resuspended in Tyrode buffer (137 mM NaCl, 2 mM KCl, 0.3 mM NaH$_2$PO$_4$, 1 mM MgCl$_2$, 5.5 mM glucose, 5 mM N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid, 12 mM NaHCO$_3$, 2 mM CaCl$_2$, pH 7.3).

### ΔΨm Measurement assay

Determination of mitochondrial potential membrane was performed in blood and in washed platelets. Blood was collected with 0.32% sodium citrate. 5 μL of blood was diluted 1/16 with

---

**Table 1. Clinical and laboratory parameters of the patients with VWF/p.V1316M mutation.**

|                        | Patient 1 | Patient 2 | Control          |
|------------------------|-----------|-----------|------------------|
| Mutation               | p.Val1316Met | p.Val1316Met |                 |
| Sex                    | M         | M         | M/F              |
| Bleeding score         | 14        | 27        | <5               |
| PFA-100 Epi and ADP    | >300      | >300      | 150 (Epi); 100 (ADP) |
| Platelet count (10$^9$/L) | 82        | 40        | 150–400         |
| Mean platelet volume (fL) | 15        | 21        | 8–10             |
| Aggregates             | Small aggregates (4%) | Small aggregates (6%) | 4%          |
| FVIII :C (U/dL)        | 62        | 39        | 50–200           |
| VWF :Ag (U/dL)         | 70        | 36        | 50–200           |
| VWF :RCo (U/dL)        | 22        | 12        | 50–200           |
| VWF multimers          | Complete loss of HMWM, Partial loss of intermediate MWM | Complete loss of HMWM | Presence of HMWM |

doi:10.1371/journal.pone.0143896.t001
Tyrode-HEPES buffer (137 mM NaCl, 2.7 mM KCl, 11.9 mM NaHCO3, 0.42 mM NaH2PO4, 1 mM MgCl2, 2 mM CaCl2, 5.5 mM glucose, 5 mM HEPES) pH 7.4 with 80 μM of PPACK to prevent fibrin formation.[12] Then diluted blood or washed platelets (100 μL at 5x10^7/mL) were incubated 30 minutes with TMRE (50 nM and 500 nM final concentration for human and mouse platelets respectively) at 37°C. Then blood was further incubated 60 minutes with or without ABT (10 μM final concentration) at 37°C and then analyzed in an Accuri C6 (Becton Dickinson) flow cytometer.

**Immunoblotting**

Washed platelets (2.5 x 10^8/mL; 300 μL) were lysed in SDS denaturing buffer (50 mM Tris, 100 mM NaCl, 50 mM NaF, 5 mM EDTA, 40 μM β-glycerophosphate, 100 μM phenylarsine oxide, 1% SDS, 5 μg/mL leupeptin, 10 μg/mL aprotinin, pH 7.4). Equal numbers of platelets were loaded and subjected to SDS-PAGE before transfer onto nitrocellulose membranes. The membranes were incubated with various primary antibodies (see Results Section), washed and immunoreactive bands were visualized using the enhanced chemiluminescence detection kit WesPico (Pierce, Rockford, IL). Images of the chemiluminescent signal were captured using a G:BOX Chemi XT16 Image System and quantified using Gene Tools version 4.0.0.0 (Syngene, Cambridge, UK).

**PS externalization assay**

PS externalization was assessed in blood and in washed platelets. Blood was collected with 0.32% sodium citrate. Then 5 μL of blood was diluted 1:16 (v:v) with Tyrode-HEPES buffer pH 7.4 with 80 μM PPACK to prevent fibrin formation.[12] Then annexin V-PE (5 μL) and an FITC-labeled antibody (10 μL) specific for CD41a, a platelet marker, were added to the blood. Washed platelets (5x10^7/mL) were mixed with annexin V-PE at a ratio of 4 μL of annexin V-PE for 20 μL of platelets and incubated at room temperature in the dark. After 15 minutes, blood or platelets were analyzed by flow cytometry (Accuri C6 flow cytometer; BD Biosciences; Le Pont de Claix, France).

**Statistical analyses**

Statistical significance was evaluated by the Student t-test for unpaired samples.

**Results**

**Apoptosis is undetectable in platelets from two patients carrying the VWF/pV1316M mutation**

We first examined apoptosis in human platelets from two patients harboring the VWF/pV1316M mutation. These patients exhibited a low platelet count (P1: 80x10^9 platelets/L and P2: 40x10^9 platelets/L), a severe bleeding tendency and large platelets (Table 1). Flow cytometry detected few spontaneous aggregates in whole blood (P1: 4% and P2: 6% versus control: 4%) (Table 1). However, blood smears showed that these aggregates were small (<4 platelets) as previously shown for P1 [11] and for P2 (S1B Fig). Compared with a normal pooled human plasma (arbitrarily set at 100%), VWF-antigen levels were 70% and 36% for patient P1 and P2 respectively.

The expression of proapoptotic proteins (Bak and Bax) and antiapoptotic (Bcl-xL) which play an essential role in apoptosis was quantified by western blotting. For these experiments an equal number of platelets was loaded for control and patients (only few aggregates (P1: 7% and P2: 2% versus control: 2%; S1A and S1B Fig) were detected by flow cytometry). Apoptotic
proteins were quantified as the ratio of each apoptotic protein expression versus 14-3-3ζ expression. Indeed 14-3-3ζ was previously shown to undergo very little biological variation, even under various pathological conditions.[13] Then, the ratio of apoptotic proteins for P1 or P2 was compared to that of control (100%). For P1, proapoptotic proteins were normal (Bak: 96% of control) or decreased (Bax: 54% of control, \( { }^{**} p = 2.9 \times 10^{-5} \)) whereas the expression of the anti-apoptotic protein Bcl-xl was increased (223% of control, \( { }^{*} p = 2.8 \times 10^{-2} \)) (Fig 1). For P2, pro-apoptotic proteins were increased reaching 190% for Bak (\( ** p = 2.3 \times 10^{-3} \)) and 350% for Bax (\( { }^{*} p = 1.4 \times 10^{-2} \)) but in parallel Bcl-xl was largely expressed (269%; \( { }^{*} p = 1.7 \times 10^{-2} \)). Altogether these results indicate a pro- and anti-apoptotic proteins balance not being in favor of apoptosis in P1 and P2.

Apoptotic proteins interacting with the mitochondrial outer membrane regulate the depolarization of \( \Delta \Psi_m \) and the release of factors leading to the activation of caspases. We next measured the \( \Delta \Psi_m \) using the cell-permeable lipophilic cationic dye TMRE which accumulates in the mitochondria in the presence or absence of a Bcl-xl antagonist (ABT-737: 10 \( \mu \)M), a positive control of apoptosis. Fig 2A shows that no \( \Delta \Psi_m \) depolarization as measured by the decrease in fluorescence of TMRE-stained washed platelets occurred in P1 (4.1% ± 0.2%) and P2 (11.4% ± 0.2%) versus control (7.2% ± 1.7%). The difference between patients and control was not significant. In the presence of a Bcl-xl antagonist (ABT-737: 10 \( \mu \)M), \( \Delta \Psi_m \) depolarization was observed reaching 21.2% and 22% ± 0.2% for P1 (n = 2) and for P2 (n = 3) versus control washed platelets (24.4% ± 1.1%) (Fig 2A), suggesting that the apoptotic machinery is functional in the patients. To avoid a potential underestimation of \( \Delta \Psi_m \) depolarization in washed patient’s platelets because aggregates may be lost during platelet preparation, we next quantified the \( \Delta \Psi_m \) depolarization in whole blood. No \( \Delta \Psi_m \) depolarization was observed in patients P1 and P2 (P1: 1.5% ± 0.2%; P2: 2.3% ± 0.2% versus control: 3.0% ± 0.1%) (Fig 2B). ABT-737 (10 \( \mu \)M) induced a significant but lower \( \Delta \Psi_m \) depolarization for patients compared with control (P1: 21.4% ± 0.8%, \( { }^{**} p = 1.4 \times 10^{-3} \); P2 12.3% ± 0.7%, \( { }^{***} p = 6.0 \times 10^{-5} \) versus control 33.9% ± 1.7%). Together these results confirmed that apoptosis does not occur in patients platelets.

We next investigated the activity of caspase-3 by measuring the presence of the active fragment (17 kDa) of caspase-3 and the proteolytic cleavage of gelsolin, its specific substrate. In P1 and P2 platelets, the active fragment of caspase-3 (17 kDa) was virtually undetectable (Fig 3A), the ratio of cleaved over uncleaved caspase-3 was below 0.01 compared with the 1:1 ratio that was observed upon incubation with ABT-737. This would mean little relevance to the thrombocytopenia issue, for which apoptosis would be expected to be massive. Moreover, cleaved 48 kDa gelsolin fragment was undetectable (Fig 3B). In contrast, fragments of caspase-3 and gelsolin were observed in the presence of ABT-737 (10 \( \mu \)M) (Fig 3A and 3B) confirming that the apoptotic machinery is functional in patients platelets.

Because calpain is activated in apoptosis, we next quantified the expression of calpain 1 in patients P1 and P2, by western blotting. We found that the expression of calpain was near normal for P1 (115% of non-apoptotic control platelets) and slightly decreased for P2 (70% of control) and that gelsolin, a substrate of calpain, was not proteolysed (Fig 3B), consistent with absence of platelet apoptosis for both patients.

Finally platelet PS exposure, a hallmark of VWF-GPIbα-mediated apoptosis [8] was measured by annexin V binding to VWD-2B platelets, as assessed by flow cytometry. In patients, PS exposure at the surface of platelets either washed or in whole blood in absence ABT-737 was low (P1: 8.2% ± 5.3% and 3.6% ± 0.2%) or slightly increased (P2: 9.9% ± 0.2%, and 23.0% ± 0.6%, \( { }^{**} p = 2.9 \times 10^{-5} \)) compared with control (2.9% ± 0.9% and 3.0% ± 0.3%) (Fig 4A and 4B). Note that for P2 platelets no depolarization of \( \Delta \Psi_m \) in blood (Fig 2B: 2.9% ± 0.2%) and no caspase 3 activation (Fig 3) were detected, strongly suggesting that the apparent increased PS...
Fig 1. Expression of apoptotic proteins in patients with VWD-type 2B. Washed platelets (2.5 x10^8 platelets/mL) from controls (C) or P1 and P2 were lysed and then equal numbers of platelets were loaded. Apoptotic proteins were assessed by immunoblotting with anti-Bak, anti-Bax, anti Bcl-xL and anti-14-3-3ζ antibodies. Data are expressed as the ratio of apoptotic protein expression versus 14-3-3ζ expression. Then, the ratio of an apoptotic protein for P1 or P2 was compared with the corresponding ratio for control (100%). Results are means ± Standard Error of the Mean (SEM) from three independent experiments. *p = 2.8.0x10^-2, **p = 2.3x10^-3, ***p = 2.9x10^-4.

doi:10.1371/journal.pone.0143896.g001
A  Washed platelets

\[ \Delta \Psi_m \text{ depolarization (\%)} \]

| ABT-737 | control | P1  | P2  |
|---------|---------|-----|-----|
| -   | +   | -   | +   |

B  Blood

\[ \Delta \Psi_m \text{ depolarization (\%)} \]

| ABT-737 | control | P1   | P2   |
|---------|---------|------|------|
| -   | +   | -   | +   |

**Statistical significance:**
- \( \text{P1: } \star \star \star \)
- \( \text{P2: } \star \star \star \)
expression in P2 platelets in whole blood is the likely consequence of the more pronounced thrombocytopenia, compared to P1: this is strongly suggested by the fact that in washed platelets and normalized counts, no PS exposure was detected on P2 platelets. The addition of ABT-737 (10 μM) showed a significant PS exposure for both patients and control whatever the model (washed platelets or blood) but lower for patients in blood conditions (P1: 71.8% ± 3.0%, **p = 1.4x10⁻³; P2: 43.4% ± 0.3%, ***p = 5.8x10⁻⁸ versus control: 85.2% ± 1.2% (Fig 4A and 4B). All these results strongly argue against apoptosis in VWD-2B platelets.

High levels of VWF/pV1316M expressed in mice deficient in VWF do not correlate with platelet apoptosis.

Because VWF at high concentration (35 μg/mL) and in the presence of ristocetin induces platelet apoptosis,[8] we next examined apoptosis in conditions of higher concentrations of VWF/p. V1316M. High VWF concentrations may occur under inflammatory conditions and may aggravate thrombocytopenia in VWD-type 2B. To mimic conditions of increased VWF levels, a mouse model for VWD-2B was used.[10] These mice exhibited VWD-2B features including prolonged tail bleeding time, thrombocytopenia and increased platelet clearance[7] making them an appropriate model to study the potential contribution of apoptosis. Blood was collected three days after the onset of VWF expression. Blood smears showed small (<10 platelets) and large (10–40 platelets) aggregates.[10] The detection of large aggregates in mice but not in patients is probably the consequence of the high VWF antigen level in mouse plasma. Indeed, compared with normal pooled mouse plasma (100%), average antigen levels were 297.3% ± 59.6% for WT mVWF and 423.1% ± 61.1% for mVWF/p.V1316M-expressing mice respectively. Mutant mVWF was associated with a severe thrombocytopenia (mVWF/p. V1316M: 301 ± 93x10⁹ platelets/L versus WT mVWF: 814 ± 73x10⁹ platelets/L).

The expression of Bak and Bax (proapoptotic proteins) was then examined in platelets. Equal numbers of platelets were loaded. Apoptotic proteins were quantified as the ratio of apoptotic protein expression versus 14-3-3ζ expression. Then, the ratio of control WT plasmid or V1316M plasmid was compared with the ratio of control pLIVE plasmid (100%). Bak expression was modestly increased in mVWF/p.V1316M-derived platelets (210% ± 26%) but not significantly different (p = 5.7x10⁻²) compared to mVWF/WT (130% ± 30%) (Fig 5). The expression of Bax was also slightly increased (mVWF/p.V1316M: 190% ± 35%, p = 1.3x10⁻¹) compared to WT-mVWF: 93% ± 7% but not significantly different. Note that proapoptotic protein Bcl-xL expression was undetectable in mice (results not shown).

We next measured the ΔΨm depolarization in the presence or absence of ABT-737. In the absence of ABT-737, no ΔΨm depolarization of washed platelets and blood was detected in either WT-mVWF (0.9% ± 0.1% and 8.1% ± 1.6%) or in mVWF/p.V1316M (0.8% ± 0.02% and 3.8% ± 0.6%) (Fig 6A and 6B) platelets. In contrast, the addition of ABT-737 (10 μM) induced a similar ΔΨm depolarization in mVWF/WT-derived platelets (20.1% ± 1.1%) and mVWF/p. V1316M-derived platelets (20.9% ± 0.1%) (Fig 6A). Identical results were obtained in blood (WT-mVWF: 52.8% ± 3.4% versus mVWF/pV1316M: 52.8% ± 2.1%) (Fig 6B). Altogether these results suggest strongly that there is no apoptosis associated with the large aggregates.

![Fig 2. ΔΨm depolarization in patients with VWD-type 2B. ΔΨm depolarization was determined A) in washed platelets and B) in blood pretreated for 30 minutes with TMRE-PE (50 nM final concentration) at 37°C. Then platelets were further incubated for 60 minutes with or without ABT-737 (10 μM final concentration) and analyzed by flow cytometry. Results are expressed as a percentage of depolarized cells. Means ± SEM from three independent experiments are shown, **p = 1.4x10⁻³ and ***p = 6.0x10⁻⁵ (unpaired Student t test).](http://example.com/fig2.png)

doi:10.1371/journal.pone.0143896.g002
Fig 3. Caspase 3 activity in patients with VWD-type 2B. Washed platelets (2.5 x 10^8 platelets/mL) pretreated or not with ABT-737 (10 µM) were lysed and caspase-3 activity was assessed by immunoblotting with A) an anti-caspase-3 antibody B) with an anti-gelsolin antibody and C) with anti-calpain 1 antibody. Results are representative of two or three independent experiments.
A  Washed platelets

![Graph showing Annexin V positive (%) for ABT-737 in washed platelets across control, P1, and P2]

B  Blood

![Graph showing Annexin V positive (%) for ABT-737 in blood across control, P1, and P2 with significance levels]

---

**ABT-737**

control  -  +  -  +  -  +

P1  P2
present in VWD-type 2B mice that high levels of VWF/p.V1316M do not correlate with platelet apoptosis in mice and that apoptosis is not involved in clearance.

To confirm the absence of the intrinsic mitochondrial pathway of apoptosis in VWD-2B platelets we next investigated the activity of caspase-3 in the presence or absence of ABT-737 (10 μM). In the absence of ABT-737, proteolytic cleavage of the active fragment (17 kDa) of caspase-3 was not observed in mice expressing mVWF/WT and mVWF/p.V1316M (Fig 7). After ABT-737 addition, full-length caspase-3 (35 kDa) decreased in both control VWF and VWF/p.V1316M while the caspase-3 active fragment (17 kDa) was detected, confirming that the apoptosis machinery is functional in mVWF/p.V1316M-derived platelets.

Finally, no PS exposure as measured by annexin V staining was observed in platelets, either washed or in whole blood in murine mVWD-2B (2.7% ± 0.8% and 2.1% ± 0.2%) or in mVWF/WT (1.0% ± 0.07% and 1.5% ± 0.6%) (Fig 8A and 8B). In contrast PS exposure was observed in the presence of ABT (10 μM) for all conditions used. Altogether our results show that apoptosis does not appear to be induced by VWF/p.V1316M, even at concentrations up to 500%.

Discussion

VWD-2B is characterized by gain-of-function mutations in the GPIbα-binding VWF-A1 domain, and which trigger constitutive binding of mutant VWF to platelet GPIb. Thrombocytopenia has long been considered a valuable explanation for the bleeding tendency in VWD-type 2B patients, given the direct correlation between this bleeding condition and platelet counts.[4] GPIbα-VWF interactions having been reported to induce apoptotic events in
platelets, we have explored the possibility that apoptosis contributed to VWD-type 2B thrombocytopenia.[8, 9]

We have thus looked for apoptosis in platelets isolated from two patients with a severe VWF-type 2B mutation (VWF/p.V1316M) and from a mouse model expressing the same mutation.[10] Our data strongly argue in favor of the conclusion that apoptosis is not involved in thrombocytopenia observed in patients with VWD-2B or in mice expressing high levels of mVWF/p.V1316M. Neither depolarization of the mitochondrial inner transmembrane potential nor caspase-3 activity were detected and the expression of the proapoptotic proteins Bak and Bax was not up-regulated even at elevated concentrations of VWF/p.V1316M. We did detect a slightly increased phosphatidyl serine expression in P2 platelets. However this increase was not correlated with an increased depolarization of the mitochondrial inner transmembrane potential. This increased PS exposure is likely to originate from a higher percentage of platelets being in an active state under basal conditions. Of note the absence of spontaneous apoptosis

![Fig 6. ΔΨm depolarization in mice expressing VWD-type 2B. ΔΨm depolarization was determined in washed platelets pretreated for 30 minutes with TMRE-PE (500 nM final concentration) at 37°C. Then platelets were incubated further for 60 minutes with or without ABT-737 (10 μM final concentration) and analyzed by flow cytometry. Results are expressed as a percentage of depolarized cells. Means ± SEM from three independent experiments are shown. **p = 2.5 x 10^{-2} and **p = 5.0 x 10^{-3} (unpaired Student t test).](#)

doi:10.1371/journal.pone.0143896.g006

![Fig 7. Caspase 3 activity in mice expressing VWD-type 2B.](#)

Washed murine platelets were pretreated or not with ABT-737 (10 μM). An equal number of platelets were lysed and loaded. Caspase-3 activity was assessed by immunoblotting with anti-caspase-3 antibody. Results are representative of three independent experiments.

doi:10.1371/journal.pone.0143896.g007
**A** Washed platelets

![Graph showing Annexin V positive (%) vs. ABT (10 μM) for different genotypes: pLIVE, WT, V1316M.]

**B** Blood

![Graph showing Annexin V positive (%) vs. ABT (10 μM) for different genotypes: pLIVE, WT, V1316M.]

(PLOS ONE | DOI:10.1371/journal.pone.0143896 December 8, 2015 14 / 16)
in patients with VWF/p.V1316M is not the result of apoptosis pathways malfunction, since the 
addition of ABT-737 (antagonist of Bcl-xL) induced a ΔΨm reduction. A final observation 
consistent with the absence of apoptosis concerns calpain 1. Despite the presence of (near) normal 
amounts in platelets of both patients, no cleavage of its substrate gelsolin was detected, 
consistent with inactive calpain 1. The presence of near normal levels of calpain 1 is opposite to 
the findings of Okita et al.,[14] who reported reduced platelet levels of calpain 1 in patients 
with the Montreal Syndrome, ie VWD-type 2B/p.V1316M. The reason for these different find-
ings is unclear.

One possible explanation for the absence of apoptosis in the patients platelets is that the 
concentration of VWF/p.V1316M antigen in the patients’ plasma is too low to trigger platelet 
apoptosis. This would explain our results contrasting with previous studies showing that plate-
let apoptosis may be induced by VWF in the presence of ristocetin,[8] but at higher VWF con-
centrations (35 μg/mL) than usually found in controls or patients (1–10 μg/mL). Similar high 
levels of VWF were found in our hydrodynamic mouse model of VWD-2B. Nevertheless, apo-
ptosis remained undetectable. The detection of large aggregates in mice but not in patients is 
probably the consequence of the high VWF antigen level in mouse plasma. In spite of large 
aggregates, apoptosis remained undetectable indicating that apoptosis is probably not induced 
during the formation of aggregates in VWD-type 2B. This suggests that VWF/ristocetin proba-
dly does not mimic VWF/p.V1316M interaction with platelets. This may indicate that the 
VWF/p.V1316M-GPIb interaction elicits signaling pathways different from that of wild-type 
VWF/GPIb interaction mediated by ristocetin. Alternatively the difference may lie in experi-
mental conditions, our observation relying on the in vivo interaction of VWF with platelets. 
Future studies are required to address this question.

Another explanation could be that those platelets having entered apoptosis in vivo are 
cleared so quickly that they are undetectable, or represent a minor fraction of the whole platelet 
population. However it appears unlikely that such a mechanism accounts for a marked throm-
bocytopenia, such as observed with the VWF/p.V1316M mutation.

Finally, because GPIbα-VWF interactions have been shown to induce platelet apoptosis in 
conditions of high but pathological (7000 s⁻¹) shear stress [8], our results do not rule out a po-
sible apoptosis under such pathological conditions. Moreover, these results do not completely 
exclude the possibility that other VWF mutations in VWD-type 2B could induce apoptosis, 
though with limited likelihood, given the strong impact of the VWF/p.V1316M mutation on 
thrombocytopenia.

In conclusion, our results strongly suggest that apoptosis is unlikely to contribute signifi-
cantly to thrombocytopenia in VWD-2B with the severe mutation VWF/p.V1316M.

Supporting Information

S1 Fig. Platelet population in patients and Blood smears. Analysis of populations of washed 
platelets from patients (A) P1 and (B) P2 by flow cytometry. Flow cytometry detected few 
aggregates for P1 and P2. (Ba) blood smears showed small aggregates. (TIF)
Acknowledgments
The authors wish to thank the patients who participated to this study.

Author Contributions
Conceived and designed the experiments: EB MB. Performed the experiments: EB AK FA AH PL MB. Analyzed the data: EB MB. Contributed reagents/materials/analysis tools: CLB CR. Wrote the paper: EB AK FA NP ODC PJL CVD JPR MB.

References
1. Ruggeri ZM. Von Willebrand factor: looking back and looking forward. Thromb Haemost. 2007; 98 (1):55–62. PMID: 17597991.
2. Bryckaert M, Rosa JP, Denis CV, Lenting PJ. Of von Willebrand factor and platelets. Cell Mol Life Sci. 2015; 72(2):307–26. doi: 10.1007/s00018-014-1743-8 PMID: 25297919; PubMed Central PMCID: PMC4284388.
3. Ginsburg D, Bowie EJ. Molecular genetics of von Willebrand disease. Blood. 1992; 79(10):2507–19. PMID: 1586703.
4. Federici AB, Mannucci PM, Castaman G, Barociani L, Bucciarelli P, Canciani MT, et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood. 2009; 113(3):526–34. doi: 10.1182/blood-2008-04-152280 PMID: 18805962.
5. Nurden P, Gobbi G, Nurden A, Enouf J, Youlyouz-Marfak I, Carubbi C, et al. Abnormal VWF modifies megakaryocytopoiesis: studies of platelets and megakaryocyte cultures from patients with von Willebrand disease type 2B. Blood. 2010; 115(13):2649–56. doi: 10.1182/blood-2009-07-231886 PMID: 20118404.
6. Nurden P, Chretien F, Pougol C, Winckler J, Borel-Derlon A, Nurden A. Platelet ultrastructural abnormalities in three patients with type 2B von Willebrand disease. Br J Haematol. 2000; 110(3):704–14. PMID: 10997984.
7. Casari C, Du V, Wu YP, Kauskot A, de Groot PG, Christophe OD, et al. Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B-associated thrombocytopenia. Blood. 2013; 122(16):2893–902. doi: 10.1182/blood-2013-03-493312 PMID: 23945153.
8. Li S, Wang Z, Liao Y, Zhang W, Shi Q, Yan R, et al. The glycoprotein Ibalpha-von Willebrand factor interaction induces platelet apoptosis. J Thromb Haemost. 2010; 8(2):341–50. doi: 10.1111/j.1538-7836.2009.03653.x PMID: 19840363.
9. van der Wal DE, Du VX, Lo KS, Rasmussen JT, Verhoeft S, Akkerman JW. Platelet apoptosis by cold-induced glycoprotein Ibalpha clustering. J Thromb Haemost. 2010; 8(11):2554–62. doi: 10.1111/j.1538-7836.2010.04043.x PMID: 20735720.
10. Rayes J, Hollestelle MJ, Legendre P, Marx I, de Groot PG, Christophe OD, et al. Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B. Blood. 2010; 115(23):4870–7. doi: 10.1182/blood-2009-11-254193 PMID: 20200350.
11. Casari C, Berrou E, Lebret M, Adam F, Kauskot A, Bohe R, et al. von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin alphabeta3. J Clin Invest. 2013; 123(12):5071–81. doi: 10.1172/JCI69458 PMID: 24270421; PubMed Central PMCID: PMC3859410.
12. Rand ML, Wang H, Bang KW, Teitel JM, Blanchette VS, Freedman J, et al. Phosphatidylserine exposure and other apoptotic-like events in Bernard-Soulier syndrome platelets. American journal of hematology. 2010; 85(8):584–92. doi: 10.1002/ajh.21768 PMID: 20658588.
13. Baumgartner R, Umlauf E, Veitinger M, Gutierrez S, Rappold E, Babeluk R, et al. Identification and validation of platelet low biological variation proteins, superior to GAPDH, actin and tubulin, as tools in clinical proteomics. Journal of proteomics. 2013; 94:540–51. doi: 10.1016/j.jprot.2013.10.015 PMID: 24284060.
14. Okita JR, Frojmovic MM, Kristopeit S, Wong T, Kunicki TJ. Montreal platelet syndrome: A defect in calcium-activated neutral proteinase (calpain). Blood-1989-74-715. PMID: 2546630.